Abivax (ABVX) Invested Capital (2021 - 2026)

Abivax's Invested Capital history runs 6 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• On a quarterly basis, Invested Capital changed N/A year-over-year to $38.4 million in Q1 2026; TTM through Mar 2026 was $185.3 million, a 48.84% increase from a year earlier, with the FY2025 full-year figure at $37.4 million, down 69.72% from the prior year.
• Invested Capital climbed to $38.4 million in Q1 2026 per ABVX's latest filing, from $37.4 million in the prior quarter.
• Across five years, Invested Capital topped out at $121.8 million in Q4 2024 and bottomed at $2.7 million in Q2 2024.
• The 5-year median for Invested Capital is $51.7 million (2022), against an average of $55.4 million.
• Biggest YoY gain for Invested Capital was 2036.23% in 2025; the steepest drop was 69.33% in 2025.
• Year by year, Invested Capital stood at $50.8 million in 2022, then jumped by 63.16% to $82.9 million in 2023, then jumped by 46.96% to $121.8 million in 2024, then plunged by 69.33% to $37.4 million in 2025, then grew by 2.68% to $38.4 million in 2026.
• Per Business Quant, the three latest ABVX Invested Capital figures stand at $38.4 million (Q1 2026), $37.4 million (Q4 2025), and $52.5 million (Q3 2025).